Valuation: Norda ASA

Market Cap 51Cr 5.41Cr 4.68Cr 4.38Cr 4Cr 7.54Cr 516.06Cr 7.66Cr 51Cr 20Cr 258.17Cr 20Cr 20Cr 859.86Cr P/E 2023 *
-
P/E 2024 3.26x
Enterprise Value 26Cr 2.79Cr 2.41Cr 2.26Cr 2.06Cr 3.88Cr 265.84Cr 3.95Cr 26Cr 10Cr 132.99Cr 10Cr 10Cr 442.94Cr EV / Sales 2023
-1.24x
EV / Sales 2024 0.4x
Free-Float
6.26%
Yield 2023 *
-
Yield 2024 32.5%
1 day+1.53%
3 months+1.53%
6 months+1.53%
Current year-13.60%
Current year 81
Extreme 81
86.4
1 year 81
Extreme 81
100
3 years 41
Extreme 41
100
5 years 41
Extreme 41
100
10 years 8
Extreme 8
100
Manager TitleAgeSince
Chief Executive Officer - 08/04/2013
Director TitleAgeSince
Chairman 54 31/01/2014
Director/Board Member 68 20/06/2013
Director/Board Member - -
Change 5-day change 1-year change 3-year change Capi.($)
+1.53%-.--%+7.87%+110.73% 4.68Cr
-0.67%+3.46%+6.43%+16.36% 5TCr
+0.89%+13.44%+491.34%+594.30% 4.44TCr
+3.08%+14.42%+24.57%+81.39% 4.08TCr
+1.38%+3.70%+34.54%+9.11% 3.98TCr
+0.85%+10.32%+21.22%+47.64% 3.25TCr
+0.08%+5.00% - - 1.69TCr
+1.99%+5.08%+38.70%+125.08% 1.68TCr
-0.14%+3.40%+5.39%+18.79% 1.4TCr
+3.56%+19.98%+86.23%+27.29% 1.32TCr
Average +1.50%+6.74%+79.59%+114.52% 2.69TCr
Weighted average by Cap. +1.49%+7.09%+107.49%+139.66%

Financials

2023 2024
Net sales 8.69Cr 91.65L 79.34L 74.16L 67.78L 1.28Cr 87Cr 1.3Cr 8.7Cr 3.41Cr 44Cr 3.44Cr 3.37Cr 145.64Cr 37Cr 3.92Cr 3.39Cr 3.17Cr 2.9Cr 5.46Cr 373.95Cr 5.55Cr 37Cr 15Cr 187.08Cr 15Cr 14Cr 623.07Cr
Net income 3.12Cr 32.87L 28.45L 26.6L 24.31L 45.81L 31Cr 46.52L 3.12Cr 1.22Cr 16Cr 1.23Cr 1.21Cr 52Cr 13Cr 1.33Cr 1.15Cr 1.07Cr 98.21L 1.85Cr 126.66Cr 1.88Cr 13Cr 4.94Cr 63Cr 4.99Cr 4.88Cr 211.03Cr
Net Debt -31Cr -3.28Cr -2.84Cr -2.66Cr -2.43Cr -4.57Cr -313Cr -4.65Cr -31Cr -12Cr -156.58Cr -12Cr -12Cr -521.51Cr -25Cr -2.62Cr -2.27Cr -2.12Cr -1.94Cr -3.66Cr -250.22Cr -3.71Cr -25Cr -9.77Cr -125.18Cr -9.85Cr -9.64Cr -416.92Cr
Logo Norda ASA
Norda ASA, formerly NorDiag ASA, is a Norway-based company active within the biotechnology sector. It develops, manufactures and markets automated solutions (instruments and tests) for sample preparation of bacterial and human DNA from difficult biological samples for use in the fields of infectious diseases, transplantation testing (HLA Typing) and others. The Company’s products include NorDiag Arrow (CE, IVD), which is a compact, automated solution for nucleic acid extractions, as well as NorDiag Bullet, 8 tip config, which is a fully automated sample preparation instrument for molecular diagnostics and can isolate from samples such as urine, swab, faces, sputum and blood. Its distribution products include Molzym GmbH and Co KG, as well as Hain Lifescience GmbH. Its customers are clinical laboratories, hospitals, research institutes, medical diagnostics and healthcare providers. It is operational through offices and laboratories in Norway, Sweden, Austria and the United States.
Employees
1
  1. Stock Market
  2. Stocks
  3. NORD Stock